Securities code: China Meheco Group Co.Ltd(600056) securities abbreviation: China Meheco Group Co.Ltd(600056) Announcement No.: Lin 2022004 China Meheco Group Co.Ltd(600056)
Abnormal stock trading announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
The daily closing price of the company’s shares has deviated from the value by more than 20% in three consecutive trading days, which is an abnormal fluctuation of stock trading.
After the company’s self-examination and verification with the controlling shareholder and actual controller, there are no major matters that should be disclosed but not disclosed.
The company is concerned about the recent rumors about the cooperation between the company and a multinational pharmaceutical company covid-19 virus treatment drugs. After verification by the company, relevant matters are under communication and negotiation, and there is still uncertainty. If the cooperation is carried out smoothly, the final use and sales of relevant drugs are also affected by factors such as epidemic prevention and control, and there is uncertainty, which has no significant impact on the company’s recent operating performance.
1、 Details of abnormal fluctuations in stock trading
China Meheco Group Co.Ltd(600056) (hereinafter referred to as “the company” or “the company”) shares have deviated from the daily closing price by more than 20% in three consecutive trading days on March 1, 2022, March 2 and March 3, 2022. According to the relevant provisions of the trading rules of Shanghai Stock Exchange, it belongs to abnormal fluctuation of stock trading.
2、 Relevant information concerned and verified by the company
(I) production and operation
According to the company’s self inspection, the company’s current production and operation activities are normal, and there are no major matters affecting the abnormal fluctuation of the company’s stock trading price.
(II) major events
According to the reply from China General Technology (Group) Holding Co., Ltd., the controlling shareholder of the company, the controlling shareholder and the actual controller of the company do not have any major asset restructuring, share issuance, acquisition, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase Bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major issues. (III) media reports, market rumors and hot concepts
The company is concerned about the recent rumors about the cooperation between the company and a multinational pharmaceutical company covid-19 virus treatment drugs. After verification by the company, relevant matters are under communication and negotiation, and there is still uncertainty. If the cooperation is carried out smoothly, the final use and sales of relevant drugs are also affected by factors such as epidemic prevention and control, and there is uncertainty, which has no significant impact on the company’s recent operating performance.
(IV) other stock price sensitive information. It is verified that during the abnormal fluctuation period of the above stock trading, the company’s directors, supervisors, senior managers and controlling shareholders did not buy or sell the company’s shares, and the company did not find any other major events that may have a great impact on the company’s share price.
3、 Relevant risk tips
(I) secondary market transaction risk
The daily closing price of the company’s shares deviated from the value by more than 20% in three consecutive trading days on March 1, 2022, March 2 and March 3, 2022, and the share price fluctuated greatly. According to the query of wind system, as of the closing on March 3, 2022, the company’s dynamic P / E ratio is 12.88 times. Please pay attention to the trading risks in the secondary market, make rational decisions and invest prudently.
(II) production and operation risks
At present, the company’s production and operation activities are normal, and there are no major matters affecting the abnormal fluctuation of the company’s stock trading price.
(III) uncertainty risk of matters or businesses involved in media reports, market rumors and hot concepts
The company is concerned about the recent rumors about the cooperation between the company and a multinational pharmaceutical company covid-19 virus treatment drugs. After verification by the company, relevant matters are under communication and negotiation, and there is still uncertainty. If the cooperation is carried out smoothly, the final use and sales of relevant drugs are also affected by factors such as epidemic prevention and control, and there is uncertainty, which has no significant impact on the company’s recent operating performance.
4、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules or the planning, negotiation, intention and agreement related to the matters, and the board of directors has not been informed that the company has matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules Information that has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
The media of the information disclosure website designated by the company is the website of Shanghai Stock Exchange (www.sse. Com. CN.) And Shanghai Securities News, China Securities News, securities times and Securities Daily. Relevant information shall be subject to the announcements published by the company on the above designated websites and media. Please invest rationally and pay attention to investment risks.
It is hereby announced.
China Meheco Group Co.Ltd(600056) board of directors March 4, 2022
